Section 01
The Evidence Base
28 studies, trials, cohorts and meta-analyses spanning 1958–2025. Covers randomised controlled trials, prospective cohorts, systematic reviews, and umbrella reviews across nine countries. Source: international peer-reviewed literature (NEJM, Lancet, JACC, JAMA Network Open, Clinical Nutrition, Frontiers in Nutrition, PLOS ONE).
67
Years of evidence (1958–2025)
8
Health outcomes with benefit
26%
Avg. CVD risk reduction (RCTs)
0
Studies with contradictory findings
0
Studies using Moroccan Picholine EVOO with documented polyphenol mg/kg
Section 02
Key Findings
Risk reduction figures derived from study-reported hazard ratios, odds ratios, and relative risks. Ranges reflect lowest and highest figures reported across all 28 studies for each outcome category. All figures represent association of highest versus lowest consumption groups.
Risk reduction by health outcome
Range across all 28 studies — minimum and maximum reported risk reduction (%) for each outcome. Highest values from secondary prevention RCTs (Lyon, GISSI) in high-risk post-MI populations.
Minimum reduction reported
Maximum reduction reported
Landmark study findings
Selected individual study risk reduction (%) — sorted highest to lowest. Blue = RCT, green = cohort, amber = meta-analysis.
Study type breakdown
28 studies classified by methodological design. RCTs provide causal evidence; cohorts provide population-level associations; meta-analyses aggregate the entire literature.
Daralbeida gap — the one missing data point across all 28 studies: Not one study in this register used a verified Moroccan Picholine Marocaine EVOO with a documented polyphenol mg/kg figure. Every percentage above belongs to someone else's oil. The Eurofins COA on the first shipment closes this gap and connects the existing evidence base to a specific product for the first time.
Section 03
Full Study Register
28 studies sorted chronologically by publication year. P = Public funding, Pr = Private/mixed. Scroll horizontally on smaller screens.
| # |
Study Name |
Type |
Year |
Country |
Institution |
N |
Follow-up |
Outcome Focus |
Key Finding |
Funding |
P/Pr |
Section 04
Studies by Country of Origin
Lead institution country for each of the 28 studies. Multi-country meta-analyses attributed to lead institution nation. Spain dominates due to the PREDIMED research network; the United States is the only non-Mediterranean country with significant representation, and notably the most recent large-scale work.
Distribution of studies by country
Country of lead institution. Percentage of 28 total studies.
Study count by country
Absolute count of studies with lead institution in each country.
Section 05
Olive Oil Consumption Per Capita
Average annual olive oil consumption in kg per person for countries represented in the study register, plus Morocco as reference. Source: International Olive Council (IOC) 2022/23 crop year data. Countries with low consumption (USA, Germany, France, China, Japan, Finland) represent the largest market opportunity — the biggest potential users are the least informed users.
Annual per capita olive oil consumption — study countries + Morocco
Kilograms per person per year — IOC 2022/23 data. Morocco shown in gold. US target market shown in red. Med. diet baseline countries shown in blue. Research-origin countries with low consumption shown in grey.
Mediterranean / high-consumption
Morocco (Daralbeida origin)
USA (primary target market)
Low-consumption study countries
The consumption gap
Greeks consume 9.3 kg/year. Americans consume 1.1 kg. The PREDIMED EVOO arm provided ~7–8 kg/year (1 litre/week). The gap between current US consumption and the therapeutic dose used in PREDIMED is the commercial opportunity.
Market opportunity in numbers
If the average American reaches the PREDIMED intervention dose (1 litre/week), annual per capita consumption would increase from 1.1 kg to 7.8 kg — a 7× uplift. At 335 million Americans, every 1% market penetration at this dose = ~26 million kg of additional demand.
7.1kg
Annual gap between current US consumption and PREDIMED dose
7×
Growth multiple if US reaches therapeutic dose
1.1kg
Current US per capita — lowest of all study-origin countries
4.0kg
Morocco per capita — 3.6× the US figure — the country that grows it